Impact of adverse drug reactions (ADR) on systemic therapy in patients (pts) with advanced or metastatic renal cell carcinoma (mRCC).

Marschner, N., Münch, A., Blumenstengel, K., Sauer, U., Müller, L., 2010.

Ann Oncol, Abstract 949 21(suppl 8), viii298. doi:10.1093/annonc/mdq525